CL2020001675A1 - Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346) - Google Patents

Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)

Info

Publication number
CL2020001675A1
CL2020001675A1 CL2020001675A CL2020001675A CL2020001675A1 CL 2020001675 A1 CL2020001675 A1 CL 2020001675A1 CL 2020001675 A CL2020001675 A CL 2020001675A CL 2020001675 A CL2020001675 A CL 2020001675A CL 2020001675 A1 CL2020001675 A1 CL 2020001675A1
Authority
CL
Chile
Prior art keywords
tumor
divisional application
cancer immunotherapy
associated peptides
peptides
Prior art date
Application number
CL2020001675A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Andrea Mahr
Oliver Schoor
Harpreet Singh
Claudia Wagner
Martina Ott
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61866862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201504502A external-priority patent/GB201504502D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2020001675A1 publication Critical patent/CL2020001675A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención se refiere a péptidos, ácidos nucleicos, vectores de expresión, células que los comprenden, kits que los comprenden, y a su utilización para preparar medicamentos contra el cáncer.
CL2020001675A 2015-03-17 2020-06-19 Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346) CL2020001675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134253P 2015-03-17 2015-03-17
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Publications (1)

Publication Number Publication Date
CL2020001675A1 true CL2020001675A1 (es) 2020-09-25

Family

ID=61866862

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2017002346A CL2017002346A1 (es) 2015-03-17 2017-09-15 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2018002427A CL2018002427A1 (es) 2015-03-17 2018-08-24 Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346)
CL2020001675A CL2020001675A1 (es) 2015-03-17 2020-06-19 Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
CL2021000623A CL2021000623A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
CL2021000624A CL2021000624A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor que se unen al complejo mayor de histocompatibilidad (mhc) y/o inducen la reacción cruzada de linfocitos t y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2017002346A CL2017002346A1 (es) 2015-03-17 2017-09-15 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2018002427A CL2018002427A1 (es) 2015-03-17 2018-08-24 Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021000623A CL2021000623A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
CL2021000624A CL2021000624A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor que se unen al complejo mayor de histocompatibilidad (mhc) y/o inducen la reacción cruzada de linfocitos t y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)

Country Status (13)

Country Link
US (14) US10449239B1 (es)
JP (3) JP6990935B2 (es)
AU (1) AU2020220071B2 (es)
CL (5) CL2017002346A1 (es)
CO (1) CO2017009101A2 (es)
CR (1) CR20210232A (es)
HK (1) HK1247842A1 (es)
IL (2) IL254081B (es)
MX (1) MX2022005570A (es)
MY (1) MY190083A (es)
PH (1) PH12017501467A1 (es)
TW (2) TWI755157B (es)
ZA (1) ZA201705219B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288581B1 (en) * 2015-04-27 2020-11-11 Cancer Research Technology Limited Method for treating cancer
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN116355851B (zh) * 2023-03-13 2023-09-08 广州医科大学附属第一医院（广州呼吸中心） 一种来源于人非小细胞肺癌的原代细胞株及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610031A (en) 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020076721A1 (en) 2000-08-07 2002-06-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2003010327A2 (en) 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060252922A1 (en) 2002-12-04 2006-11-09 Macina Roberto A Compositions, splice variants and methods relating to colon specific genes and proteins
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
NZ582822A (en) 2007-07-27 2012-06-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
PT2183361E (pt) * 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US20140154691A1 (en) * 2011-06-22 2014-06-05 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer
US20140065620A1 (en) 2011-12-29 2014-03-06 Mayo Foundation For Medical Education And Research Nucleic acids for detecting breast cancer
WO2013134860A1 (en) * 2012-03-16 2013-09-19 University Health Network Cancer biomarkers and methods of use
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Also Published As

Publication number Publication date
IL254081B (en) 2022-06-01
ZA201705219B (en) 2019-06-26
JP2024041860A (ja) 2024-03-27
US11007258B2 (en) 2021-05-18
CR20210232A (es) 2022-06-24
JP7478718B2 (ja) 2024-05-07
MY190083A (en) 2022-03-25
US10898561B2 (en) 2021-01-26
TW202124428A (zh) 2021-07-01
PH12017501467A1 (en) 2018-01-15
TW202124417A (zh) 2021-07-01
US10449239B1 (en) 2019-10-22
US20230065320A1 (en) 2023-03-02
CO2017009101A2 (es) 2017-11-30
CL2021000624A1 (es) 2021-08-06
US20200268861A1 (en) 2020-08-27
US11007257B2 (en) 2021-05-18
JP2020120659A (ja) 2020-08-13
US10729755B1 (en) 2020-08-04
US20200316183A1 (en) 2020-10-08
IL254081A0 (en) 2017-10-31
MX2022005570A (es) 2022-06-09
US20230051035A1 (en) 2023-02-16
IL280879A (en) 2021-04-29
US20200405830A1 (en) 2020-12-31
US10576135B2 (en) 2020-03-03
HK1247842A1 (zh) 2018-10-05
US20190388531A1 (en) 2019-12-26
CL2021000623A1 (es) 2021-07-23
AU2020220071A1 (en) 2020-09-03
US20210322527A1 (en) 2021-10-21
US20200230222A1 (en) 2020-07-23
US11116826B2 (en) 2021-09-14
US10561718B2 (en) 2020-02-18
TWI755158B (zh) 2022-02-11
US10668138B1 (en) 2020-06-02
AU2020220071B2 (en) 2022-06-02
CL2018002427A1 (es) 2018-10-12
JP6990935B2 (ja) 2022-02-15
JP2022046465A (ja) 2022-03-23
US10792350B2 (en) 2020-10-06
US20230094790A1 (en) 2023-03-30
CL2017002346A1 (es) 2018-03-09
TWI755157B (zh) 2022-02-11
US20200338175A1 (en) 2020-10-29
US20210228698A1 (en) 2021-07-29
US20190314473A1 (en) 2019-10-17
US20200147192A1 (en) 2020-05-14
US20190388530A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
ECSP18082207A (es) Neoantígenos y métodos de su uso
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
ECSP17027870A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
CL2020001675A1 (es) Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
UY35965A (es) Anticuerpos humanos contra pd?l1
BR112019012343A2 (pt) anticorpos il-11ra
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
CL2022003377A1 (es) Péptidos y combinaciones para uso en inmunoterapia contra el cáncer de páncreas y otros cánceres (solicitud divisional 201703235)
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
CL2023000708A1 (es) Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2018002279A1 (es) Péptidos, ácidos nucleicos y células para la utilización en inmunoterapia contra el cáncer (solicitud divisional 201600227)
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso